Other languages Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Real-time Estimate Cboe BZX Other stock markets 12:43:34 07/05/2024 am IST			5-day change	1st Jan Change
2.97 ^USD	+2.06%		-4.19%	+58.39%

02/05	Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
30/04	Protara Therapeutics, Inc. announced that it has received $44.998327 million in funding from a group of investors	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Protara Therapeutics, Inc Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral Nutrition	05/04
Protara Therapeutics, Inc. Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC	05/04
Protara Therapeutics, Inc. Announces Resignation of Jathin Bandari as Chief Medical Officer, Effective April 11, 2024	19/03
Protara Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Protara Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
Proteon Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Top Premarket Gainers	12/03
Top Premarket Decliners	12/02
Top Premarket Decliners	17/01
Protara Therapeutics Says 5 of 6 Patients in Dose Escalation Portion of Bladder Cancer Trial Showed Recurrence-Free Survival	30/11
Protara Therapeutics, Inc. Announces Presentation of Additional Encouraging Data from Phase 1A Advanced-1 Trial of Tara-002 in Nmibc At the 24Th Annual Meeting of the Society of Urologic Oncology	30/11
Protara Therapeutics Q3 Loss Widens; Files for $300 Million Mixed-Securities Shelf Registration	03/11
Protara Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
Proteon Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	03/11
Protara Therapeutics Doses First Patient in Phase 1b/2 Bladder Cancer Trial; Shares Rise	20/23/20
Protara Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03
Proteon Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	03/23/03
Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	04/23/04
Protara Therapeutics Receives Regulatory Clearance from FDA to Commence Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations	02/23/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Other languages

Filters